Cambrex Corporation, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, announced that it has signed a definitive agre...
Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced that it has completed a new 600 m2 fa...
Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced it will double the liquid packaging c...
Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, announced that it has completed the acquisition...
Cambrex, the leading manufacturer of small molecule innovator and generic APIs and finished dosage forms, announced it has entered into a definitive agreement to acquire Avista Pharma Solutions.
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms announced that it is to establish a center of ...
Cambrex Corporation announced it has entered into a definitive agreement to acquire Halo Pharma, a leading dosage form CDMO for approximately $425 million.
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, announced that it will expand research and development capabilities at its site in Paullo, Milan, Italy.
Cambrex, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, announced that it has completed the installation of multiple continuous flow reactor platforms at its US facility.
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic APIs, announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant
Cambrex Corporation held an opening ceremony with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies
Cambrex Corporation announced that it has completed the installation of new, large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden
Cambrex Corporation announced that it is expanding its High Point, North Carolina, facility with the addition of a new $3.2 million, 11,000 sq.ft. analytical laboratory
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK